The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration

Neuropeptides

Volumn 44, Issue 5, 2010, Pages 373-383

  Cochaud, Stéphanie ^a   Chevrier, Lucie ^a   Meunier, Annie Claire ^a   Brillet, Thomas ^a   Chadéneau, Corinne ^a   Muller, Jean Marc ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Actin cytoskeleton; Glioblastoma cell lines; Migration; Proliferation; Small GTPases; VIP receptors

Indexed keywords

GUANOSINE TRIPHOSPHATASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PROTEIN CDC42; RAC1 PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 77956191559     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.06.003     Document Type: Article

References (41)

1. Allalunis-Turner M.J., Barron G.M., Day R.S., Dobler K.D., Mirzayans R. Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat. Res. 1993, 134:349-354.
2. Alleaume C., Eychene A., Harnois T., Bourmeyster N., Constantin B., Caigneaux E., Muller J.M., Philippe M. Vasoactive intestinal peptide-induced neurite remodeling in human neuroblastoma SH-SY5Y cells implicates the Cdc42 GTPase and is independent of Ras-ERK pathway. Exp. Cell Res. 2004, 299:511-524.
3. Brenneman D.E., Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 1996, 97:2299-2307.
4. Cameron D.B., Galas L., Jiang Y., Raoult E., Vaudry D., Komuro H. Cerebellar cortical-layer-specific control of neuronal migration by pituitary adenylate cyclase-activating polypeptide. Neuroscience 2007, 146:697-712.
5. Demuth T., Berens M.E. Molecular mechanisms of glioma cell migration and invasion. J. Neurooncol. 2004, 70:217-228.
6. Dufes C., Alleaume C., Montoni A., Olivier J.C., Muller J.M. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro. J. Mol. Neurosci. 2003, 21:91-102.
7. Fabry M., Cabrele C., Hocker H., Beck-Sickinger A.G. Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. Peptides 2000, 21:1885-1893.
8. Fernández-Martínez A.B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate 2009, 69:774-786.
9. Gozes I., Brenneman D.E. A new concept in the pharmacology of neuroprotection. J. Mol. Neurosci. 2000, 14:61-68.
10. Gozes I., McCune S.K., Jacobson L., Warren D., Moody T.W., Fridkin M., Brenneman D.E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 1991, 257:959-966.
11. Guan C.X., Zhang M., Qin X.Q., Cui Y.R., Luo Z.Q., Bai H.B., Fang X. Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells. Peptides 2006, 27:3107-3114.
12. Heraud C., Hilairet S., Muller J.M., Leterrier J.F., Chadeneau C. Neuritogenesis induced by vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and peptide histidine methionine in SH-SY5y cells is associated with regulated expression of cytoskeleton mRNAs and proteins. J. Neurosci. Res. 2004, 75:320-329.
13. Holland E.C. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. USA 2000, 97:6242-6244.
14. Jaggi M., Prasad S., Singh A.T., Praveen R., Dutt S., Mathur A., Sharma R., Gupta N., Ahuja R., Mukherjee R., Burman A.C. Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Invest New Drugs 2008, 26:489-504.
15. Laburthe M., Couvineau A., Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007, 28:1631-1639.
16. Ladwein, M., Rottner, K., 2008. On the Rho'd: the regulation of membrane protrusions by Rho-GTPases. In: FEBS Lett. pp. 2066-2074.
17. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 2001, 166:2522-2530.
18. Lutz E.M., Ronaldson E., Shaw P., Johnson M.S., Holland P.J., Mitchell R. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Mol. Cell Neurosci. 2006, 31:193-209.
19. Martin J.L., Rose K., Hughes G.J., Magistretti P.J. [mono[125I]iodo-Tyr10, MetO17]-Vasoactive intestinal polypeptide. Preparation, characterization, and use for radioimmunoassay and receptor binding. J. Biol. Chem. 1986, 261:5320-5327.
20. Masmoudi-Kouki O., Gandolfo P., Castel H., Leprince J., Fournier A., Dejda A., Vaudry H., Tonon M.C. Role of PACAP and VIP in astroglial functions. Peptides 2007, 28:1753-1760.
21. Mayer C., Popanda O., Zelezny O., von Brevern M.C., Bach A., Bartsch H., Schmezer P. DNA repair capacity after gamma-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes. DNA Repair (Amst.) 2002, 1:237-250.
22. Mehler M.F. Mechanisms regulating lineage diversity during mammalian cerebral cortical neurogenesis and gliogenesis. Results Probl. Cell Differ. 2002, 39:27-52.
23. Moody T.W., Leyton J., Chan D., Brenneman D.C., Fridkin M., Gelber E., Levy A., Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res. Treat. 2001, 68:55-64.
24. Moody T.W., Zia F., Draoui M., Brenneman D.E., Fridkin M., Davidson A., Gozes I. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. 1993, 90:4345-4349.
25. Muller J.M., Debaigt C., Goursaud S., Montoni A., Pineau N., Meunier A.C., Janet T. Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update. Peptides 2007, 28:1655-1666.
26. Muller J.M., Lelievre V., Becq-Giraudon L., Meunier A.C. VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. Mol. Neurobiol. 1995, 10:115-134.
27. Muller J.M., Philippe M., Chevrier L., Heraud C., Alleaume C., Chadeneau C. The VIP-receptor system in neuroblastoma cells. Regul. Pept. 2006, 137:34-41.
28. Nagakawa O., Murata J., Junicho A., Matsuda T., Fujiuchi Y., Fuse H., Saiki I. Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptor-transfected DU-145 prostate cancer cells (DU-145/AR). Cancer Lett. 2002, 176:93-99.
29. Ogasawara M., Murata J., Ayukawa K., Saimi I. Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Cancer Lett. 1997, 116:111-116.
30. Ogasawara M., Murata J., Kamitani Y., Hayashi K., Saiki I. Inhibition by vasoactive intestinal polypeptide (VIP) of angiogenesis induced by murine Colon 26-L5 carcinoma cells metastasized in liver. Clin. Exp. Metastasis 1999, 17:283-291.
31. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005, 64:479-489.
32. Pence J.C., Shorter N.A. The autocrine function of vasoactive intestinal peptide on human neuroblastoma cell growth and differentiation. Arch. Surg. 1993, 128:591-595.
33. Quigley, M.R., Post, C., Ehrlich, G., 2007. Some speculation on the origin of glioblastoma. Neurosurg. Rev. 30, 16-20 (discussion 20-11).
34. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J. Nucl. Med. 1995, 36:1846-1853.
35. Robberecht P., Woussen-Colle M.C., Vertongen P., De Neef P., Hou X., Salmon I., Brotchi J. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. Peptides 1994, 15:661-665.
36. Sakai Y., Hashimoto H., Shintani N., Katoh H., Negishi M., Kawaguchi C., Kasai A., Baba A. PACAP activates Rac1 and synergizes with NGF to activate ERK1/2, thereby inducing neurite outgrowth in PC12 cells. Brain Res. Mol. Brain Res. 2004, 123:18-26.
37. Sharma A., Walters J., Gozes Y., Fridkin M., Brenneman D., Gozes I., Moody T.W. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells. J. Mol. Neurosci. 2001, 17:331-339.
38. Vertongen P., Camby I., Darro F., Kiss R., Robberecht P. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides 1996, 30:491-496.
39. Vescovi A.L., Galli R., Reynolds B.A. Brain tumour stem cells. Nat. Rev. Cancer 2006, 6:425-436.
40. Yamazaki D., Kurisu S., Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005, 96:379-386.
41. Zupan V., Hill J.M., Brenneman D.E., Gozes I., Fridkin M., Robberecht P., Evrard P., Gressens P. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. J. Neurochem. 1998, 70:2165-2173.